Surf Therapeutics reaches $6M total with additional financing following positive first-in-human RA data
Summary
Surf Therapeutics raised additional financing following positive first-in-human data from their bioelectronic rheumatoid arthritis clinical study, bringing total funding to $6M. The company's early RA data adds to the growing evidence for the cholinergic anti-inflammatory pathway as a therapeutic target, following Setpoint Medical's landmark Nature publication.
Why it matters
Surf Therapeutics securing additional financing post-positive FIH data at a modest total funding level reflects the capital efficiency possible for bioelectronic medicine companies with a clear mechanistic target and a proven patient population (RA biologic-refractory) established by Setpoint Medical. Surf can benefit from Setpoint's trail-blazing regulatory and clinical work.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial